Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 3/20 | 0.78 |
| ▸ | PNP | P00491 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.67 |
| ▸ | P2RY1 | P47900 | 8/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | P2RY11 | Q96G91 | 3/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.58 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.56 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.56 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.56 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.56 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.56 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.55 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Chlorodeoxyadenosine Triphosphate SCHEMBL29760737 | 1.00 | NT5E (0.78) | NT5EPNPLMNATP53HTT | |
| 2-Chlorodeoxyadenosine Triphosphate SCHEMBL1064481 | 1.00 | NT5E (0.78) | NT5EPNPLMNATP53HTT | |
| SCHEMBL8900163 | 0.99 | NT5E (0.79) | NT5EPNPLMNATP53HTT | |
| SCHEMBL10351553 | 0.92 | NT5E (0.84) | NT5EPNPLMNATP53HTT | |
| SCHEMBL27179019 | 0.92 | NT5E (0.84) | NT5EPNPLMNATP53HTT | |
| Ammonia Solution, Strong SCHEMBL10352165 | 0.92 | NT5E (0.84) | NT5EPNPLMNATP53HTT | |
| SCHEMBL285024 | 0.92 | NT5E (0.84) | NT5EPNPLMNATP53HTT | |
| SCHEMBL4820794 | 0.91 | NT5E (0.67) | NT5EPNPLMNATP53HTT | |
| SCHEMBL17117823 | 0.91 | NT5E (0.67) | NT5EPNPLMNATP53HTT | |
| SCHEMBL17117775 | 0.91 | NT5E (0.64) | NT5EPNPLMNATP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003055890-A1 | THIENOPYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| WO-2003055489-A1 | 2,4-DIAMINO-PYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| WO-2003055866-A1 | QUINAZOLINE AND QUINOLINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | claimed |
| US-12351613-B2 | Production of glycoproteins using manganese | AMGEN INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4430174-A1 | PRODUCTION OF THERAPEUTIC PROTEINS | Amgen Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023086793-A1 | PRODUCTION OF THERAPEUTIC PROTEINS | AMGEN INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-4155385-A1 | IMPROVED PRODUCTION OF GLYCOPROTEINS USING MANGANESE | Amgen Inc. (US) | 2023-03-29 | — | — | EP | disclosed |
| EP-1957630-B2 | IMPROVED PRODUCTION OF GLYCOPROTEINS USING MANGANESE | AMGEN INC (US) | 2023-03-29 | — | — | EP | disclosed |
| US-20220402986-A1 | PRODUCTION OF GLYCOPROTEINS USING MANGANESE | AMGEN INC. | 2022-12-22 | — | — | US | disclosed |
| US-20210179710-A1 | COMBINATION IMMUNOTHERAPY AND CHEMOTHERAPY FOR THE TREATMENT OF A HEMATOLOGICAL MALIGNANCY | ACTINIUM PHARMACEUTICALS, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210047381-A1 | Production of Glycoproteins Using Manganese | AMGEN INC. (US) | 2021-02-18 | — | — | US | disclosed |
| WO-2003055890-A1 | THIENOPYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | disclosed |
| WO-2003055489-A1 | 2,4-DIAMINO-PYRIMIDINE DERIVATIVE COMPOUNDS AS INHIBITORS OF PROLYLPEPTIDASE, INDUCERS OF APOPTOSIS AND CANCER TREATMENT AGENTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-10 | — | — | WO | disclosed |
| US-20030119732-A1 | CDDO-compounds and combination therapies thereof | BOARD OF | 2003-06-26 | — | — | US | disclosed |
| WO-2002047611-A2 | CDDO-COMPOUNDS AND COMBINATION THERAPIES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2002-06-20 | — | — | WO | disclosed |
| US-5661136-A | 2-halo-2'-fluoro ARA adenosines as antinoplastic agents | SOUTHERN RESEARCH INSTITUTE (US) | 1997-08-26 | — | — | US | disclosed |
| EP-0595826-A4 | 2'-FLUORO-2-SUBSTITUTED ADENINYL ARABINOSIDES AS ANTI-CANCER AGENTS | SOUTHERN RES INST (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5384310-A | Antitumor | SOUTHERN RESEARCH INSTITUTE (US) | 1995-01-24 | — | — | US | disclosed |
| EP-0595826-A1 | 2'-FLUORO-2-SUBSTITUTED ADENINYL ARABINOSIDES AS ANTI-CANCER AGENTS | Southern Research Institute (US) | 1994-05-11 | — | — | EP | disclosed |
| WO-1992020347-A1 | 2'-FLUORO-2-SUBSTITUTED ADENINYL ARABINOSIDES AS ANTI-CANCER AGENTS | SOUTHERN RESEARCH INSTITUTE (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047381-A1 | Production of Glycoproteins Using Manganese | SLC17A5, NEU4, NEU2 | NT5E 1293/4885PNP 1883/4885LMNA 2987/4885 |
| US-20030119732-A1 | CDDO-compounds and combination therapies thereof | CD74, BAD, PDCD4 | NT5E 2613/4885PNP 3702/4885LMNA 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.